October 27, 2025 • New York City
New York Strategic Alignment
MSO.ai/Omni × Wound Physicians × 91 Life/Eagle Nest/Matrix

Duration: ≈ 1h 30m

Attendees: Houman Farzian (MSO.ai / Omni Wound Physicians) • Bleron (CEO, 91 Life / Eagle Nest / Matrix) • Binn (COO, 91 Life)

Strategic Agenda
Technology Vision

AI-OS & Tokenized Architecture

Partnership Structure

Entity Roles & Governance

Capitalization

Fund-Raise Strategy

Expansion Pathway

Domestic & Global Rollout

Governance & Risk

Mitigation Framework

Next Steps

Immediate Actions

1. Technology Vision
1.1 AI-OS & Tokenized Architecture

Bleron demonstrated 91 Life's AI Operating System (AI-OS), designed as a fully tokenized, modular architecture. Each patient variable—diagnosis, note, or device data—is converted into mathematical tokens that render a unified, one-click interface.

  • Goal: Make 90% of patient information accessible within one click, promoting real-time visibility across care settings.
  • Core Technology:
  • Microservice-based "leaf" design linking patient data to devices, EMR, imaging, and prior notes.
  • Tokenized note generation that transforms each variable into a structured data object for analytics and billing.
  • Ontology-based configuration allows different specialties (wound care, cardiology, nephrology) to run within the same framework.
  • Future Use Case: The AI-OS architecture supports "Healthcare in a Box" — a digitally deployable clinic model for remote, institutional, or battlefield care.
1.2 Eagle Nest Framework

Eagle Nest serves as the global vehicle for healthcare platform deployment, operating beyond the U.S. compliance landscape. Its mission is to build self-contained digital health ecosystems in emerging markets.

Target Regions

Albania, North Macedonia, Croatia, Ethiopia, Senegal, Saudi Arabia, Qatar, UAE.

Strategic Output

A single-box model integrating patient EMR, diagnostics, logistics, and AI triage tools.

Pilot Timeline

First full baseline system by Q1 2026.

1.3 Integration Vision with MSO.ai
AIOS Health
AI Operating System for Health

MSO.ai's strengths in compliance, licensing, and operational scale complement 91 Life's AI-OS infrastructure. The parties agreed to pursue a layered integration:

  • MSO.ai / Omni provides the clinical footprint, operational know-how, and U.S. licensing across 50 states.
  • 91 Life / Matrix delivers AI and data infrastructure via the Eagle Nest global health architecture.
  • Result: A joint ecosystem—AIOS Health (AI Operating System for Health)—designed to serve both domestic and international medical networks.
2. MSO.ai & Omni Strengths
2.1 Operational Excellence

Houman outlined MSO.ai's vertically integrated mobile wound-care model, already functional nationwide. The business manages clinical staffing, medical billing, compliance, and EMR.

Modular Expansion

MSO.ai's structure allows modular expansion without clinical ownership conflicts.

Proven Success

Proven success through Omni Wound Physicians, capable of buying or managing practices using physician partners' licenses.

2.2 Compliance and Governance

Omni's approach to separate revenue swim lanes ensures transparency:

Skin Graft Supply

Through partners like Venture Medical

MSO Management

MSO management and scheduling

Billing Services

Billing and documentation services

2.3 Franchising and Expansion

The franchise model proposed by Houman includes:

Phase 1: Franchise Network
  • Franchisees (mobile wound practices) joining under the Omni–Venture–MSO umbrella.
  • Access to training, documentation, billing optimization, and compliance infrastructure.
  • Mandated procurement of supplies through the network, ensuring control over revenue flow.
Phase 2: Strategic Acquisitions

Phase 2 envisions selective acquisitions of struggling practices under physician-licensed entities to expand footprint.

3. Partnership & Entity Structure
3.1 Separation of Domains

Both parties agreed that success depends on maintaining clear boundaries:

3.2 Governance Logic
  • Joint projects will be treated as collaborative ventures rather than merged ownerships.
  • Financial interests defined by participation models (revenue share or equity blocks) rather than integration.
  • Each company retains independent operations to protect investor confidence and maintain funding eligibility.
3.3 Entity Evolution

91 Life has evolved into a multi-branch structure:

91 Life

Focused solely on cardiology (Heart+, ablation, rhythm analysis).

Matrix

AI R&D and tokenized tech stack (~$7–8M revenue, 85% gross margin).

Eagle Nest

Healthcare OS deployment globally.

4. Capitalization and Fund-Raise Strategy
4.1 91 Life Capital Plan
$25–30M
Series A Target

Internal Commitments: $10M (from Cliff and other investors).

Financial Snapshot (2025)
  • Revenue: $7.5M (up from $3.5M in 2024)
  • Gross Margin: 81%
  • Positive EBITDA: ~$2M
  • Internal R&D contribution: $8M from Matrix profits and Bleron's reinvestment
Use of Funds Allocation
Investor Landscape
  • Negotiations with Silversmith, Susquehanna, and other high-liquidity funds.
  • Focused on strategic investors that tolerate diversification and understand AI healthcare cycles.
  • Valuation discussions ongoing; preference for equity, not debt.
4.2 MSO.ai Funding Flexibility

Houman signaled potential investment participation from MSO.ai and Omni if clear equity or revenue upside is structured, avoiding passive capital deployment. Consensus: participation model must match risk, deliverables, and integration value.

5. Expansion Pathway
5.1 Domestic (U.S.)
Phase 1 – Mobile Wound Care

Immediate implementation leveraging Omni's licensed footprint and existing reimbursement streams.

Phase 2 – Freestanding ER / Micro-Hospital

Extend technology stack into high-acuity settings; Omni to lead regulatory navigation.

Phase 3 – Cardiology Integration

Combine 91 Life's Heart+ monitoring with Omni's ER network to create continuous patient loops.

5.2 Global (Eagle Nest)
  • Healthcare in a Box: Deploy AIOS Health in modular units adaptable for rural or emerging markets.
  • Government pilots targeted for Albania, Middle East, and Africa.
  • Initial rollout under Albanian Ministry of Health (2026) with partnerships across telemedicine, EMR, and AI triage.
  • Expected to expand via franchise and licensing models to maintain control and scalability.
6. Risk & Governance Analysis